Johnson & Johnson Net Profit Margin 2010-2024 | JNJ
Current and historical net profit margin for Johnson & Johnson (JNJ) from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue. Johnson & Johnson net profit margin for the three months ending September 30, 2024 was .
| Johnson & Johnson Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-09-30 |
$87.70B |
$14.68B |
16.74% |
| 2024-06-30 |
$86.58B |
$38.02B |
43.91% |
| 2024-03-31 |
$85.65B |
$38.48B |
44.92% |
| 2023-12-31 |
$85.16B |
$35.15B |
41.28% |
| 2023-09-30 |
$76.31B |
$34.62B |
45.37% |
| 2023-06-30 |
$74.96B |
$13.05B |
17.42% |
| 2023-03-31 |
$77.46B |
$12.72B |
16.43% |
| 2022-12-31 |
$79.99B |
$17.94B |
22.43% |
| 2022-09-30 |
$77.21B |
$19.16B |
24.81% |
| 2022-06-30 |
$80.55B |
$18.37B |
22.80% |
| 2022-03-31 |
$79.85B |
$19.83B |
24.84% |
| 2021-12-31 |
$78.74B |
$20.88B |
26.52% |
| 2021-09-30 |
$91.45B |
$17.88B |
19.55% |
| 2021-06-30 |
$89.19B |
$17.77B |
19.92% |
| 2021-03-31 |
$84.21B |
$15.12B |
17.95% |
| 2020-12-31 |
$82.58B |
$14.71B |
17.82% |
| 2020-09-30 |
$80.86B |
$16.99B |
21.01% |
| 2020-06-30 |
$80.50B |
$15.19B |
18.86% |
| 2020-03-31 |
$82.73B |
$17.17B |
20.75% |
| 2019-12-31 |
$82.06B |
$15.12B |
18.42% |
| 2019-09-30 |
$81.71B |
$14.15B |
17.32% |
| 2019-06-30 |
$81.33B |
$16.33B |
20.08% |
| 2019-03-31 |
$81.59B |
$14.68B |
17.99% |
| 2018-12-31 |
$81.58B |
$15.30B |
18.75% |
| 2018-09-30 |
$81.38B |
$1.54B |
1.89% |
| 2018-06-30 |
$80.68B |
$1.37B |
1.70% |
| 2018-03-31 |
$78.69B |
$1.25B |
1.58% |
| 2017-12-31 |
$76.45B |
$1.30B |
1.70% |
| 2017-09-30 |
$74.36B |
$15.83B |
21.28% |
| 2017-06-30 |
$72.53B |
$16.34B |
22.52% |
| 2017-03-31 |
$72.17B |
$16.51B |
22.87% |
| 2016-12-31 |
$71.89B |
$16.54B |
23.01% |
| 2016-09-30 |
$71.60B |
$15.94B |
22.27% |
| 2016-06-30 |
$70.88B |
$15.03B |
21.20% |
| 2016-03-31 |
$70.18B |
$15.55B |
22.15% |
| 2015-12-31 |
$70.07B |
$15.41B |
21.99% |
| 2015-09-30 |
$70.52B |
$14.72B |
20.87% |
| 2015-06-30 |
$71.88B |
$16.11B |
22.41% |
| 2015-03-31 |
$73.59B |
$15.92B |
21.63% |
| 2014-12-31 |
$74.33B |
$16.32B |
21.96% |
| 2014-09-30 |
$74.43B |
$17.32B |
23.27% |
| 2014-06-30 |
$73.54B |
$15.55B |
21.15% |
| 2014-03-31 |
$71.92B |
$15.06B |
20.94% |
| 2013-12-31 |
$71.31B |
$13.83B |
19.40% |
| 2013-09-30 |
$70.52B |
$12.88B |
18.26% |
| 2013-06-30 |
$69.99B |
$12.87B |
18.38% |
| 2013-03-31 |
$68.59B |
$10.44B |
15.22% |
| 2012-12-31 |
$67.22B |
$10.85B |
16.14% |
| 2012-09-30 |
$65.92B |
$8.50B |
12.90% |
| 2012-06-30 |
$64.87B |
$8.74B |
13.47% |
| 2012-03-31 |
$65.00B |
$10.11B |
15.55% |
| 2011-12-31 |
$65.03B |
$9.67B |
14.87% |
| 2011-09-30 |
$64.42B |
$11.40B |
17.69% |
| 2011-06-30 |
$63.40B |
$11.61B |
18.32% |
| 2011-03-31 |
$62.13B |
$12.28B |
19.77% |
| 2010-12-31 |
$61.59B |
$13.33B |
21.65% |
| 2010-09-30 |
$62.49B |
$13.60B |
21.76% |
| 2010-06-30 |
$62.59B |
$13.53B |
21.61% |
| 2010-03-31 |
$62.50B |
$13.29B |
21.26% |
| 2009-12-31 |
$61.90B |
$12.27B |
19.82% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$380.982B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
